Petrović, Bojana

Link to this page

Authority KeyName Variants
4b0705cc-5c0f-43b2-a850-b1b60baab32d
  • Petrović, Bojana (2)
Projects
No records found.

Author's Bibliography

Alterations of c-Myc and c-erbB-2 genes in ovarian tumours

Pastor, Tibor; Popović, Branka; Gvozdenović, Ana; Boro, Aleksandar; Petrović, Bojana; Novaković, Ivana; Puzović, Dragana; Luković, Ljiljana; Milašin, Jelena

(Srpsko lekarsko društvo, Beograd, 2009)

TY  - JOUR
AU  - Pastor, Tibor
AU  - Popović, Branka
AU  - Gvozdenović, Ana
AU  - Boro, Aleksandar
AU  - Petrović, Bojana
AU  - Novaković, Ivana
AU  - Puzović, Dragana
AU  - Luković, Ljiljana
AU  - Milašin, Jelena
PY  - 2009
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1502
AB  - Introduction. According to clinical and epidemiological studies, ovarian cancer ranks fifth in cancer deaths among women. The causes of ovarian cancer remain largely unknown but various factors may increase the risk of developing it, such as age, family history of cancer, childbearing status etc. This cancer results from a succession of genetic alterations involving oncogenes and tumour suppressor genes, which have a critical role in normal cell growth regulation. Mutations and/or overexpression of three oncogenes, c-erbB-2, c-Myc and K-ras, and of the tumour suppressor gene p53, have been frequently observed in a sporadic ovarian cancer. Objective. The aim of the present study was to analyze c-Myc and c-erbB-2 oncogene alterations, specifically amplification, as one of main mechanisms of their activation in ovarian cancers and to establish a possible association with the pathogenic process. Methods. DNA was isolated from 15 samples of malignant and 5 benign ovarian tumours, using proteinase K digestion, followed by phenol-chloroform isoamyl extraction and ethanol precipitation. C-Myc and c-erbB-2 amplification were detected by differential PCR. The level of gene copy increase was measured using the Scion image software. Results. The amplification of both c-Myc and c-erbB-2 was detected in 26.7% of ovarian epithelial carcinoma specimens. Only one tumour specimen concomitantly showed increased gene copy number for both studied genes. Interestingly, besides amplification, gene deletion was also detected (26.7% for c-erbB-2). Most of the ovarian carcinomas with alterations in c-Myc and c-erbB-2 belonged to advanced FIGO stages. Conclusion. The amplification of c-Myc and c-erbB-2 oncogenes in ovarian epithelial carcinomas is most probably a late event in the pathogenesis conferring these tumours a more aggressive biological behaviour. Similarly, gene deletions point to genomic instability in epithelial carcinomas in higher clinical stages as the result of clonal evolution and selection.
AB  - Uvod. Kliničke i epidemiološke studije su pokazale da je kancer jajnika peti po redu uzročnik smrti žena. Iako postoje mnogi predisponirajući faktori, kao što su starosna dob, porodična istorija kancera, sterilnost, broj rođene dece i dr., tačni uzroci nastanka tumora jajnika još nisu poznati. Zna se, međutim, da je kancer jajnika rezultat akumulacije različitih genskih alteracija, od kojih su najznačajnije mutacije, odnosno povišena ekspresija određenih onkogena, kao što su c-myc, c-erbB-2 i K-ras, i tumor-supresorskih gena, od kojih je najvažniji p53. Cilj rada. Cilj istraživanja je bio da se ispitaju alteracije c-myc i c-erbB-2 (pre svega njihove amplifikacije), najčešćeg mehanizma aktivacije ovih onkogena, u epitelnim karcinomima jajnika, i utvrde njihove potencijalne uloge u patogenezi ovog tipa neoplazmi u našoj populaciji. Metode rada. DNK je izolovana iz 15 uzoraka malignih tumora i pet uzoraka benignih tumora jajnika. Amplifikacije onkogena c-myc i c-erbB-2 ustanovljavane su metodom diferencijalne reakcije lančanog umnožavanja DNK (engl. differential polymerase chain reaction - dPCR). Nivo amplifikacije određen je nakon denzitometrijskog merenja traka na gelu primenom programa Scion image. Rezultati. Amplifikacija i gena c-myc i c-erbB-2 otkrivena je u četiri uzorka (26,7%) epitelnog karcinoma jajnika. Jedan od ispitivanih uzoraka je imao simultanu amplifikaciju oba gena. Većina uzoraka bila je visokog stadijuma prema kriterijumima Međunarodne federacije za ginekologiju i akušerstvo (International Federation of Gynecology and Obstetrics - FIGO). Zanimljivo je da je pored amplifikacije nezavisno ustanovljena i delecija gena c-erbB-2 u 26,7% karcinoma. Svi karcinomi sa delecijama su takođe pripadali visokim kliničkim stadijumima. Zaključak. Amplifikovani onkogeni c-myc i c-erbB-2 su odlika kasnih stadijuma epitelnih maligniteta i verovatno jedan od razloga njihovog agresivnog biološkog ponašanja. Slično tome, i delecija gena erb obeležava uznapredovale stadijume bolesti i ukazuje na genomsku nestabilnost koja se javlja u epitelnim karcinomima kao rezultat evolucije i selekcije različitih tumorskih klonova.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Alterations of c-Myc and c-erbB-2 genes in ovarian tumours
T1  - Alteracije onkogena c-myc i c-erbB-2 u malignim tumorima jajnika
VL  - 137
IS  - 1-2
SP  - 47
EP  - 51
DO  - 10.2298/SARH0902047P
ER  - 
@article{
author = "Pastor, Tibor and Popović, Branka and Gvozdenović, Ana and Boro, Aleksandar and Petrović, Bojana and Novaković, Ivana and Puzović, Dragana and Luković, Ljiljana and Milašin, Jelena",
year = "2009",
abstract = "Introduction. According to clinical and epidemiological studies, ovarian cancer ranks fifth in cancer deaths among women. The causes of ovarian cancer remain largely unknown but various factors may increase the risk of developing it, such as age, family history of cancer, childbearing status etc. This cancer results from a succession of genetic alterations involving oncogenes and tumour suppressor genes, which have a critical role in normal cell growth regulation. Mutations and/or overexpression of three oncogenes, c-erbB-2, c-Myc and K-ras, and of the tumour suppressor gene p53, have been frequently observed in a sporadic ovarian cancer. Objective. The aim of the present study was to analyze c-Myc and c-erbB-2 oncogene alterations, specifically amplification, as one of main mechanisms of their activation in ovarian cancers and to establish a possible association with the pathogenic process. Methods. DNA was isolated from 15 samples of malignant and 5 benign ovarian tumours, using proteinase K digestion, followed by phenol-chloroform isoamyl extraction and ethanol precipitation. C-Myc and c-erbB-2 amplification were detected by differential PCR. The level of gene copy increase was measured using the Scion image software. Results. The amplification of both c-Myc and c-erbB-2 was detected in 26.7% of ovarian epithelial carcinoma specimens. Only one tumour specimen concomitantly showed increased gene copy number for both studied genes. Interestingly, besides amplification, gene deletion was also detected (26.7% for c-erbB-2). Most of the ovarian carcinomas with alterations in c-Myc and c-erbB-2 belonged to advanced FIGO stages. Conclusion. The amplification of c-Myc and c-erbB-2 oncogenes in ovarian epithelial carcinomas is most probably a late event in the pathogenesis conferring these tumours a more aggressive biological behaviour. Similarly, gene deletions point to genomic instability in epithelial carcinomas in higher clinical stages as the result of clonal evolution and selection., Uvod. Kliničke i epidemiološke studije su pokazale da je kancer jajnika peti po redu uzročnik smrti žena. Iako postoje mnogi predisponirajući faktori, kao što su starosna dob, porodična istorija kancera, sterilnost, broj rođene dece i dr., tačni uzroci nastanka tumora jajnika još nisu poznati. Zna se, međutim, da je kancer jajnika rezultat akumulacije različitih genskih alteracija, od kojih su najznačajnije mutacije, odnosno povišena ekspresija određenih onkogena, kao što su c-myc, c-erbB-2 i K-ras, i tumor-supresorskih gena, od kojih je najvažniji p53. Cilj rada. Cilj istraživanja je bio da se ispitaju alteracije c-myc i c-erbB-2 (pre svega njihove amplifikacije), najčešćeg mehanizma aktivacije ovih onkogena, u epitelnim karcinomima jajnika, i utvrde njihove potencijalne uloge u patogenezi ovog tipa neoplazmi u našoj populaciji. Metode rada. DNK je izolovana iz 15 uzoraka malignih tumora i pet uzoraka benignih tumora jajnika. Amplifikacije onkogena c-myc i c-erbB-2 ustanovljavane su metodom diferencijalne reakcije lančanog umnožavanja DNK (engl. differential polymerase chain reaction - dPCR). Nivo amplifikacije određen je nakon denzitometrijskog merenja traka na gelu primenom programa Scion image. Rezultati. Amplifikacija i gena c-myc i c-erbB-2 otkrivena je u četiri uzorka (26,7%) epitelnog karcinoma jajnika. Jedan od ispitivanih uzoraka je imao simultanu amplifikaciju oba gena. Većina uzoraka bila je visokog stadijuma prema kriterijumima Međunarodne federacije za ginekologiju i akušerstvo (International Federation of Gynecology and Obstetrics - FIGO). Zanimljivo je da je pored amplifikacije nezavisno ustanovljena i delecija gena c-erbB-2 u 26,7% karcinoma. Svi karcinomi sa delecijama su takođe pripadali visokim kliničkim stadijumima. Zaključak. Amplifikovani onkogeni c-myc i c-erbB-2 su odlika kasnih stadijuma epitelnih maligniteta i verovatno jedan od razloga njihovog agresivnog biološkog ponašanja. Slično tome, i delecija gena erb obeležava uznapredovale stadijume bolesti i ukazuje na genomsku nestabilnost koja se javlja u epitelnim karcinomima kao rezultat evolucije i selekcije različitih tumorskih klonova.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Alterations of c-Myc and c-erbB-2 genes in ovarian tumours, Alteracije onkogena c-myc i c-erbB-2 u malignim tumorima jajnika",
volume = "137",
number = "1-2",
pages = "47-51",
doi = "10.2298/SARH0902047P"
}
Pastor, T., Popović, B., Gvozdenović, A., Boro, A., Petrović, B., Novaković, I., Puzović, D., Luković, L.,& Milašin, J.. (2009). Alterations of c-Myc and c-erbB-2 genes in ovarian tumours. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 137(1-2), 47-51.
https://doi.org/10.2298/SARH0902047P
Pastor T, Popović B, Gvozdenović A, Boro A, Petrović B, Novaković I, Puzović D, Luković L, Milašin J. Alterations of c-Myc and c-erbB-2 genes in ovarian tumours. in Srpski arhiv za celokupno lekarstvo. 2009;137(1-2):47-51.
doi:10.2298/SARH0902047P .
Pastor, Tibor, Popović, Branka, Gvozdenović, Ana, Boro, Aleksandar, Petrović, Bojana, Novaković, Ivana, Puzović, Dragana, Luković, Ljiljana, Milašin, Jelena, "Alterations of c-Myc and c-erbB-2 genes in ovarian tumours" in Srpski arhiv za celokupno lekarstvo, 137, no. 1-2 (2009):47-51,
https://doi.org/10.2298/SARH0902047P . .
3
2
1

Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas

Petrović, Bojana; Perović, Milica; Novaković, Ivana; Atanacković, Jasmina; Popović, Branka; Luković, Ljiljana; Petković, Spasoje

(Vojnomedicinska akademija - Institut za naučne informacije, Beograd, 2006)

TY  - JOUR
AU  - Petrović, Bojana
AU  - Perović, Milica
AU  - Novaković, Ivana
AU  - Atanacković, Jasmina
AU  - Popović, Branka
AU  - Luković, Ljiljana
AU  - Petković, Spasoje
PY  - 2006
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1271
AB  - Background/aim: Among the genes involved in ovarian carcinogenesis, there has been increased interest in tumor-suppressor genes p53 and BRCA1. Both of the genes make control of cell cycle, DNA repair and apoptosis. The p53 is a "genome guardian" inactivated in more than 50% of human cancers, while BRCA1 mutations are found mostly in breast and ovarian cancer. The aim of this investigation was to establish the frequency of loss of heterozygosity (LOH) in the regions of the genes p53 and BRCA1 in ovarian carcinomas, and to analyze the association of LOH with the disease stage and prognosis. Methods. We analyzed 20 patients with a confirmed diagnosis of epithelilal ovarian carcinoma. DNA for molecular-genetic analysis was extracted from the tumor tissue and blood as normal tissue of each person. Microsatellite markers of the regions of genes p53 and BRCA1 were amplified by PCR method. The determination of allelic status of microsatellites and detection of LOH was performed after PAA gel electroforesis. Results. Both of the analyzed microsatellite markers were informative in 13/20 (65%) cases. In the region of gene p53, LOH was established in 4/13 (30.7%) tumors. One of them had histological gradus G1, one had gradus G2, and two of them had gradus G3, while all were with the International Federation of Gynecology and Obstetrics (FIGO) IIIc stage. In the region of gene BRCA1, LOH was detected in 5/13 (38.5%) tumors. Four of them had histological gradus G2, and one had gradus G3, while by the (FIGO) classification one was with stage Ib, one was with stage IIIb, while the three were with stage IIIc. LOH in both of the analyzed regions was detected in one tumor (7.7%), with histological gradus G3 and the FIGO IIIc stage. Conclusion. The frequency of LOH in epthelial ovarian carcinomas was 30.7% and 38.5% for p53 and BRCA1 gene regions, respectively. Most of tumors with LOH had histological gradus G2 or G3, and the clinical FIGO stage IIIc, suggesting the association of this occurrence with a later phase of the disease.
AB  - Uvod/cilj: Među genima uključenim u proces ovarijumske karcinogeneze pažnju privlače tumor-supresor geni p53 i BRCA1. Oba gena kontrolišu ćelijski ciklus, reparaciju DNK i apoptozu. Dok je p53 univerzalni "čuvar genoma" čija se inaktivacija nalazi u više od 50% maligniteta čoveka, mutacije BRCA1 se nalaze pre svega kod karcinoma dojke i ovrijuma. Istraživanje je sprovedeno sa ciljem da se utvrdi učestalost gubitka heterozigotnosti (LOH) u regionima gena p53 i BRCA1 kod karcinoma ovarijuma i da se ispita njegova korelacija sa stadijumom i prognozom bolesti. Metode. Ispitivanjem je obuhvaćeno 20 bolesnica sa potvrđenom dijagnozom karcinoma ovarijuma. Za molekularno genetičku analizu DNK izolovana je iz tumorskog tkiva i krvi kao kontrolnog zdravog tkiva iste osobe. Mikrosatelitni markeri u regionu gena p53 i BRCA1 umnožavani su PCR metodom, a analiza alelskog statusa i pojave LOH je vršena nakon poliakril-amidinom (PAA) gel elektroforeze. Rezultati. Oba analizirana mikrosatelitna markera bila su informativna u po 13 do 20 slučajeva (65%). U regionu gena p53 nađen je LOH u 4 od 13 slučajeva (30,7%). Po jedan od ovih tumora bio je histološkog gradusa G1 i G2, a dva histološkog gradusa G3, dok je FIGO stadijum u svim slučajevima bio IIIc. U regionu gena BRCA1 LOH je nađen u 5 od 13 slučajeva (38,5%). Od ovih uzoraka četiri su bila histološkog gradusa G2, a jedan histološkog gradusa G3. Po FIGO klasifikaciji jedan uzorak sa LOH bio je u stadijumu Ic, jedan u stadijumu IIIb, dok su tri bila u stadijumu IIIc. Istovremeni gubitak heterozigotnosti za oba ispitivana gena detektovan je u jednom uzorku histološkog gradusa G3, u stadijumu IIIc, što čini 7,7%. Zaključak. Učestalost LOH kod karcinoma ovarijuma iznosila je 30,7% u regionu gena p53, odnosno 38,5% u regionu gena BRCA1. Najveći broj tumora sa LOH bio je histološkog gradusa G2 ili G3, u kliničkom stadijumu IIIc, pa se može zaključiti da je ova pojava povezana sa kasnijom fazom razvoja bolesti.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas
T1  - Analiza gubitka heterozigotnosti tumor-supresor gena p53 i BRCA1 kod karcinoma ovarijuma
VL  - 63
IS  - 9
SP  - 813
EP  - 818
DO  - 10.2298/VSP0609813P
ER  - 
@article{
author = "Petrović, Bojana and Perović, Milica and Novaković, Ivana and Atanacković, Jasmina and Popović, Branka and Luković, Ljiljana and Petković, Spasoje",
year = "2006",
abstract = "Background/aim: Among the genes involved in ovarian carcinogenesis, there has been increased interest in tumor-suppressor genes p53 and BRCA1. Both of the genes make control of cell cycle, DNA repair and apoptosis. The p53 is a "genome guardian" inactivated in more than 50% of human cancers, while BRCA1 mutations are found mostly in breast and ovarian cancer. The aim of this investigation was to establish the frequency of loss of heterozygosity (LOH) in the regions of the genes p53 and BRCA1 in ovarian carcinomas, and to analyze the association of LOH with the disease stage and prognosis. Methods. We analyzed 20 patients with a confirmed diagnosis of epithelilal ovarian carcinoma. DNA for molecular-genetic analysis was extracted from the tumor tissue and blood as normal tissue of each person. Microsatellite markers of the regions of genes p53 and BRCA1 were amplified by PCR method. The determination of allelic status of microsatellites and detection of LOH was performed after PAA gel electroforesis. Results. Both of the analyzed microsatellite markers were informative in 13/20 (65%) cases. In the region of gene p53, LOH was established in 4/13 (30.7%) tumors. One of them had histological gradus G1, one had gradus G2, and two of them had gradus G3, while all were with the International Federation of Gynecology and Obstetrics (FIGO) IIIc stage. In the region of gene BRCA1, LOH was detected in 5/13 (38.5%) tumors. Four of them had histological gradus G2, and one had gradus G3, while by the (FIGO) classification one was with stage Ib, one was with stage IIIb, while the three were with stage IIIc. LOH in both of the analyzed regions was detected in one tumor (7.7%), with histological gradus G3 and the FIGO IIIc stage. Conclusion. The frequency of LOH in epthelial ovarian carcinomas was 30.7% and 38.5% for p53 and BRCA1 gene regions, respectively. Most of tumors with LOH had histological gradus G2 or G3, and the clinical FIGO stage IIIc, suggesting the association of this occurrence with a later phase of the disease., Uvod/cilj: Među genima uključenim u proces ovarijumske karcinogeneze pažnju privlače tumor-supresor geni p53 i BRCA1. Oba gena kontrolišu ćelijski ciklus, reparaciju DNK i apoptozu. Dok je p53 univerzalni "čuvar genoma" čija se inaktivacija nalazi u više od 50% maligniteta čoveka, mutacije BRCA1 se nalaze pre svega kod karcinoma dojke i ovrijuma. Istraživanje je sprovedeno sa ciljem da se utvrdi učestalost gubitka heterozigotnosti (LOH) u regionima gena p53 i BRCA1 kod karcinoma ovarijuma i da se ispita njegova korelacija sa stadijumom i prognozom bolesti. Metode. Ispitivanjem je obuhvaćeno 20 bolesnica sa potvrđenom dijagnozom karcinoma ovarijuma. Za molekularno genetičku analizu DNK izolovana je iz tumorskog tkiva i krvi kao kontrolnog zdravog tkiva iste osobe. Mikrosatelitni markeri u regionu gena p53 i BRCA1 umnožavani su PCR metodom, a analiza alelskog statusa i pojave LOH je vršena nakon poliakril-amidinom (PAA) gel elektroforeze. Rezultati. Oba analizirana mikrosatelitna markera bila su informativna u po 13 do 20 slučajeva (65%). U regionu gena p53 nađen je LOH u 4 od 13 slučajeva (30,7%). Po jedan od ovih tumora bio je histološkog gradusa G1 i G2, a dva histološkog gradusa G3, dok je FIGO stadijum u svim slučajevima bio IIIc. U regionu gena BRCA1 LOH je nađen u 5 od 13 slučajeva (38,5%). Od ovih uzoraka četiri su bila histološkog gradusa G2, a jedan histološkog gradusa G3. Po FIGO klasifikaciji jedan uzorak sa LOH bio je u stadijumu Ic, jedan u stadijumu IIIb, dok su tri bila u stadijumu IIIc. Istovremeni gubitak heterozigotnosti za oba ispitivana gena detektovan je u jednom uzorku histološkog gradusa G3, u stadijumu IIIc, što čini 7,7%. Zaključak. Učestalost LOH kod karcinoma ovarijuma iznosila je 30,7% u regionu gena p53, odnosno 38,5% u regionu gena BRCA1. Najveći broj tumora sa LOH bio je histološkog gradusa G2 ili G3, u kliničkom stadijumu IIIc, pa se može zaključiti da je ova pojava povezana sa kasnijom fazom razvoja bolesti.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas, Analiza gubitka heterozigotnosti tumor-supresor gena p53 i BRCA1 kod karcinoma ovarijuma",
volume = "63",
number = "9",
pages = "813-818",
doi = "10.2298/VSP0609813P"
}
Petrović, B., Perović, M., Novaković, I., Atanacković, J., Popović, B., Luković, L.,& Petković, S.. (2006). Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 63(9), 813-818.
https://doi.org/10.2298/VSP0609813P
Petrović B, Perović M, Novaković I, Atanacković J, Popović B, Luković L, Petković S. Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas. in Vojnosanitetski pregled. 2006;63(9):813-818.
doi:10.2298/VSP0609813P .
Petrović, Bojana, Perović, Milica, Novaković, Ivana, Atanacković, Jasmina, Popović, Branka, Luković, Ljiljana, Petković, Spasoje, "Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas" in Vojnosanitetski pregled, 63, no. 9 (2006):813-818,
https://doi.org/10.2298/VSP0609813P . .
1
1